<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00357019</url>
  </required_header>
  <id_info>
    <org_study_id>TPO 09/99 NAAXIA SINE Phase IV</org_study_id>
    <nct_id>NCT00357019</nct_id>
  </id_info>
  <brief_title>Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis</brief_title>
  <official_title>Study of the Clinical and Biological Efficacity of NAAXIA SINE® in Vernal Keratoconjunctivitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratoires Thea</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Laboratoires Thea</source>
  <brief_summary>
    <textblock>
      To assess the clinical and biological efficacity of preservative free NAAGA eyes drops in
      vernal keratoconjunctivitis
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The objective of this pilot study is to evaluate the clinical and biological efficacy of
      preservative free NAAGA eyedrops in VKC –by in particular the levels of ECP and MPO in tears-
      comparatively to the activity of levocabastine eyedrops.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date>October 2002</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ECP tear concentration</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance</measure>
  </secondary_outcome>
  <condition>Keratoconjunctivitis, Vernal</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>N-acetyl-aspartyl-glutamate (NAAXIA Sine)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with vernal keratoconjunctivitis,

          -  mild or moderate : clinical score &gt;3 and &lt;= 14, calculated from 4 major symptoms
             (itching, tearing, photophobia, foreign body sensation) and 6 major clinical signs
             (conjunctival erythema, conjunctival chemosis, discharge, papillae, limbal infiltrates
             and corneal epithelial disease)

          -  age &gt;= 4 years old

        Exclusion Criteria:

          -  no occurrence of ocular trauma or infection (within the 3 months preceding the study),

          -  no ocular medical treatment (topical or not) within the 5 days preceding the study,

          -  no ocular laser (within the 3 previous months),

          -  no ocular surgery (within the previous year),

          -  patient who signs the informed consent form (or his/her parents or legal guardian in
             the case of underage patient).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andréa LEONARDI, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinica Oculistica, Padova (Italy)</affiliation>
  </overall_official>
  <verification_date>July 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2006</study_first_submitted>
  <study_first_submitted_qc>July 26, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 27, 2006</study_first_posted>
  <last_update_submitted>July 26, 2006</last_update_submitted>
  <last_update_submitted_qc>July 26, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 27, 2006</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Isospaglumic acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

